Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence B Snyder

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Virology|July 31, 2013
Characterizations of HCV NS5A replication complex inhibitorsDonald R O'Boyle Ii, Jin-Hua Sun, Peter T Nower, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2013
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivativesMakonen Belema, Van N Nguyen, Denis R St Laurent, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2016
Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool boxHong Huang, Andrew P Degnan, Anand Balakrishnan, et al.
Nature|April 23, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Richard E Nettles, Makonen Belema, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5Fukang Yang, Lawrence B Snyder, Anand Balakrishnan, et al.
Bioorganic & Medicinal Chemistry Letters|May 5, 2005
Biaryl isoxazolinone antibacterial agentsClaude A Quesnelle, Patrice Gill, Stephan Roy, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Virology|July 31, 2013
Characterizations of HCV NS5A replication complex inhibitorsDonald R O'Boyle Ii, Jin-Hua Sun, Peter T Nower, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2013
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivativesMakonen Belema, Van N Nguyen, Denis R St Laurent, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2016
Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool boxHong Huang, Andrew P Degnan, Anand Balakrishnan, et al.
Nature|April 23, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Richard E Nettles, Makonen Belema, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5Fukang Yang, Lawrence B Snyder, Anand Balakrishnan, et al.
Bioorganic & Medicinal Chemistry Letters|May 5, 2005
Biaryl isoxazolinone antibacterial agentsClaude A Quesnelle, Patrice Gill, Stephan Roy, et al.
Pageof 3